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There are limited data about the role of endoscopic ultrasound-guided tissue acquisition
(EUS-TA), by fine needle aspiration (EUS-FNA) or biopsy (EUS-FNB), in the evaluation of
the adrenal glands (AG). The primary aim was to assess the diagnostic yield and safety.
The secondary aims were the malignancy predictors, and to create a predictive model of
malignancy.
Methods
This was a retrospective nationwide study involving all Spanish hospitals experienced in
EUS-TA of AGs. Inclusion period was from April-2003 to April-2016. Inclusion criteria: all
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consecutive cases that underwent EUS-TA of AGs. EUS and cytopathology findings were
evaluated. Statistical analyses: diagnostic accuracy of echoendoscopist’s suspicion using
cytology by EUS-TA, as gold standard; multivariate logistic regression model to predict
tumor malignancy.
Results
A total of 204 EUS-TA of AGs were evaluated. Primary tumor locations were lung70%, oth-
ers19%, and unknown11%. AG samples were adequate for cytological diagnosis in 91%,
and confirmed malignancy in 60%. Diagnostic accuracy of the endosonographer’s suspicion
was 68%.
The most common technique was: a 22-G (65%) and cytological needle (75%) with suc-
tion-syringe (66%). No serious adverse events were described. The variables most associ-
ated with malignancy were size>30mm (OR2.27; 95%CI, 1.16–4.05), heterogeneous echo-
pattern (OR2.11; 95%CI, 1.1–3.9), variegated AG shape (OR2.46; 95%CI, 1–6.24), and
endosonographer suspicion (OR17.46; 95%CI, 6.2–58.5). The best variables for a predic-
tive multivariate logistic model of malignancy were age, sex, echo-pattern, and AG-shape.
Conclusions
EUS-TA of the AGs is a safe, minimally invasive procedure, allowing an excellent diagnostic
yield. These results suggest the possibility of developing a pre-EUS procedure predictive
malignancy model.
Introduction
The adrenal gland (AG) is a frequent location where metastatic cells settle in patients with
known primary tumor, mainly of the lung, involving a poor prognosis and a change in man-
agement. Previous data show that the incidence of AG masses in patients with lung cancer
ranges from 4% to 18%, of which 40% are malignant [1,2]. However, up to two-thirds of adre-
nal masses, in lung cancer, are benign adenomas [3]. The data provided by imaging techniques
cannot accurately differentiate between a benign and a malignant mass in clinical practice, and
the need to obtain material is common [4–6].
The available data have shown that percutaneous image-guided tissue acquisition (TA) of
the AG has a high sensitivity and accuracy in diagnosing AG lesions. However this technique
yields nondiagnostic samples in up to 19% of cases and is not exempt from adverse events
(AE), such as needle tract metastasis, hemorrhage, and pneumothorax [7–10].
On the other hand, endoscopic ultrasound-guided TA, by fine needle aspiration
(EUS-FNA) or fine needle biopsy (EUS-FNB) has proven to be very effective in obtaining sam-
ples of various targets (lymph nodes, subepithelial tumours, and pancreas). To date, however,
there are few studies published showing that EUS-FNA in the study of AG is a minimally inva-
sive technique with less AE compared with percutaneous guided punctures [3, 10–13]. It is
reported that EUS-FNA of AGs is sensitive and useful to differentiate between malignant and
benign masses in cases of suspected enlarged AG by imaging tests [3]. Other reports manifest
that some EUS features can be associated with malignancy (e.g., abnormal shape of the AG),
but the data are limited [12,13].
EUS-guided TA of adrenal glands
PLOS ONE | https://doi.org/10.1371/journal.pone.0216658 June 6, 2019 2 / 16
The primary aim of this multicenter study was to analyze the diagnostic yield and safety of
EUS-TA in the study of AG. Our secondary aims were to determine predictors of malignancy,
and to create a preclusive predictive model of malignancy.
Methods
Patients and study characteristics
This was a retrospective study, consisting of a noncomparative review of a nationwide database
involving all Spanish hospitals experienced in EUS-TA of AG. All partners of the Spanish
Group of Endoscopic Ultrasound were invited by mail to participate. Finally, 17 Spanish cen-
ters accepted the invitacion. Inclusion period: from April 2003 to April 2016. Inclusion Crite-
ria: All AGs (right and left) punctured by EUS during the inclusion period. Exclusion criteria:
loss of contact or information after the procedure. A CRF was designed by the IP center and
recollected as a database from the other centers.
The following variables were reviewed: demographic details, clinical data, staging proce-
dures, endoscopic findings, technical details, cytological data, medication with potential risk-
bleeding, follow-up data, incidents, and AEs. All imaging parameters were reviewed and taken
from the original written reports. This project was developed in accordance with the ethical
approval of the Institutional Review Board (Comité Ético de Investigación Clı́nica, Hospital
Universitari de Bellvitge, code PR344/15, 7 january 2016).
EUS guided TA technique
All patients provided written informed consent previous to the procedure. All EUS-guided TA
were performed by an experienced endosonographer. Deep sedation was assisted by endosco-
pist or anesthesiologist, depending on the sedation protocol of each center. A linear array
echoendoscope (Olympus GF-UCT140-AL5 or UCT-180, Pentax EG-3870UTK or EG-
3270UK, Fujifilm EG-580UT) was used to identify and puncture the suspected AG. Left AGs
were evaluated from the stomach, and right AGs from the duodenum. EUS-guided puncture
was performed using a fine needle (25 or 22G in size), either cytological (EchoTipUltra, Cook;
ExpectEndoscopic Ultrasound Aspiration Needle, BostonSC; BeaconFNA exchange system,
Medtronic-Covidien) or cytohistopathological (EchoTip ProCore, Cook; SharkCoreFNB
exchange system, Medtronic-Covidien). Color Doppler imaging was used to avoid interposal
vessels. The suction technique applied, if any (stylet slow-pull vs. standard suction), and type
and size of needle were items selected at the discretion of the endosonographer. In patients
with antiplatelet or anticoagulant therapy, the recommendations of the international guide-
lines were followed (i.e., European Society of Gastrointestinal Endoscopy or British Society of
Gastroenterology, 2008) [14]. EUS-guided FNA of a left AG example is shown in Fig 1.
EUS image characteristics
The AGs were classified into four types based on morphology and shape: (i) seagull shape; (ii)
seagull shape with a nodule or enlargement of one limbs, (iii) global enlarged AG preserving
the seagull shape, (iv) variegated morphology (Fig 2).
The following measurements were made according to the EUS image: AG length was the
greatest extension between the end of the two wings, and the thickness was measured at the
widest body of the AG. The echogenicity was classified as hypoechoic, hyperechoic, or isoe-
choic. The echo-pattern was divided into homogeneous and heterogeneous.
Finally, the suspected diagnosis was collected according to the experienced endosonogra-
pher’s judgement: suspicion of benignity, malignancy, or undetermined AG.
EUS-guided TA of adrenal glands
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Cytological examination
Samples were prepared in the procedure room as a rapid on-site evaluation (ROSE) or without
ROSE, depending of each center’s protocol. The cytology was categorized according to the fol-
lowing groups: malignant, suspicion of malignancy, benign, atypical cells, and insufficient
sample. All specimens were examined by a cytopathologist for a definitive diagnosis. Immuno-
histochemistry data were recorded. Final diagnoses were: normal AG, adenoma of AG, pheo-
chromocytoma, and metastasis of known tumour or unknown primary tumor.
Imaging procedures
Computed tomography (CT), scan evaluation: the morphology of the AG was assessed as
normal or pathological, according to the radiologists of each center (increase of global size,
presence of nodules or masses, irregular margins). The largest AG diameter (mm) was
recorded.
Positron emission tomography (PET) scan study: the SUV (standard uptake value) of the
affected AG was analyzed in comparison with the baseline collection from the patient’s liver in
the same study according to one of the following options: hypercaptation, normocaptation, or
hypocaptation.
Statistical analysis
Nominal categorical variables were described by the number of cases, the percentage of the
total for category, and the number of missing data. Ordinal categorical variables were
described as nominal categorical, or by the number of cases, median, interquartile range, and
number of missing data. Continuous variables were described by the number of cases, mean,
standard deviation, median, first and third quartile, and number of missing data.
Diagnostic accuracy of echoendoscopist’s suspicion was analysed using cytology obtained
by EUS-TA, as gold standard. Sensivity (S), specifity (Sp), predicte values (PV) and area under
the ROC curve, were estimated.Diagnostic performance of EUS-guided TA was defined as the
Fig 1. A 63-year-old woman with adenocarcinoma of the lung and a suspicous enlarged adrenal gland. A Endoscopic ultrasound-guided fine-needle aspiration of
the adrenal gland with a dominant nodule. B Adenocarcinoma of the adrenal gland histopathology. H&E, orig. mag. ×400. Courtesy of Dr. Isabel Catala.
https://doi.org/10.1371/journal.pone.0216658.g001
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total amount of conclusive citopathology results (malignancy plus benignity) excluding the
inconclusive results (atypical cells, suspect, insufficient sample).
Dependent variable of the study was cytology result. Independent variables of the study
were CT scan morphology, PET scan uptake, echogenicity, echo pattern, endoscopist suspi-
cion, AG size, AG shape and puncture technique features.
A multivariate logistic model was estimated to cytology result. Odds ratios (OR) and confi-
dence interval at 95% were reported. The model was fitted using stepways selection focusing
on lowering the Akaike Information Criteria because it penalizes the model for complexity.
Model goodness of fit was evaluated using the Chi-square statistic to compare observed vs
expected. To evaluate discrimination, the c statistic of Hosmer-Lemeshow was used, which for
dichotomous outcome variables is equivalent to the area under the ROC curve (Receiver Oper-
ating Characteristic). The Hosmer-Lemeshow test is a goodness of fit especially for risk predic-
tion models. A goodness of fit test measures how well your data fits the model. This test is
usually accompained by a classifcation table of observed and expected frequencies.
Whenever possible, estimators were accompanied by a confidence interval at 95%. Statisti-
cal significance was set at a probability level<0.05. The statistical package used to process the
data and carry out the analysis was R version 3.2.5 for Windows. (S1 and S2 Dataset).
Fig 2. EUS images of four adrenal gland morphology stablished patterns. A Usual ‘seagull shape’. B Nodule located in a lateral wing. C Global enlargement
conserving the ‘seagull shape’. D Variegated morphology.
https://doi.org/10.1371/journal.pone.0216658.g002
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Results
Patient data
A total of 200 patients and 204 AGs were collected, with a mean age of 65 years (SD 9.7),
mostly men (152; ratio 3.1). The most common indication of EUS-guided puncture was a
patient with primary pulmonary tumor, and the left AG was more usual. Demographic and
clinical characteristics are detailed in Table 1.
Endoscopic and imaging procedures
Technical aspects of EUS-guided puncture are summarized in Table 2. The standard suction,
with syringe, was the most frequently used modality (66.18%), and the median number of
passes was 2.0 (interquartile range: 1.0 to 3.0). Most of the deep sedations were controlled by
an anesthesiologist (67.16%), and the rest by endoscopists (32.35%).
Data related to the imaging for the staging are detailed in Table 3. A pathological morphol-
ogy in the CT scan report and a hypercaptation in the PET scan were the most common find-
ings. Information related to the EUS findings is reflected in Table 4: hypoechogenicity,
heterogeneous pattern, and a seagull shape with enlargement of one of the limbs, or variegated
were noteworthy.
The diagnostic yield was 91.17%: malignant plus benign final diagnostic results. Samples
were nondiagnostic in 8.83% including atypia (0.98%), suspicious but not conclusive (2.94%),
and insufficient (4.90%) (Table 5). No significant differences between FNA or FNB needles
were found.
Endosonographer suspicion based on the EUS image, was classified as benign or malignant
in 81% of EUS procedures (19% was undetermided). Diagnostic accuracy of this was 68%. In
Fig 3 are detailed S, Sp and PVs for the endosonographer suspicion using cytology, obtained
by EUS-TA, as gold standard.
Table 1. Clinical and demographic characteristics.
Clinical and demographics
n = 200 P / 204 AG
















APA, antiplatelet agents; P, Patients; AG, Adrenal gland
DOAC, direct oral anticoagulant; SD, Standard deviation
Another tumors: biliopancreatic (8); liver (4); digestive tract (8); adrenal gland (1); gynecological (7); hematological
(4); kidney (3); melanoma (1); granulomatous disease (1); sarcoma (1).
https://doi.org/10.1371/journal.pone.0216658.t001
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Safety
Only one case of self-limiting post-procedural fever was detected, with negative blood tests. It
is of note that 10.5% AGs were treated with anticoagulant therapy and 19% were treated with
antiplatelet therapy, without any cases of bleeding. Two cases of unknown pheochromocytoma
were punctures without concomitant hypertensive crises during the EUS procedure. In the
majority of cases, no specific study for pheochromocytoma was performed previous to the
endoscopy procedure. No procedure-related mortality was reported.
Univariate and multivariate analysis
A lower age, pathological image in CT scan, hypercaptation in PET scan, variegated AG shape,
size > 30mm, heterogeneous EUS pattern, and suspicion of malignancy by the endoscopist
were statistically associated with a malignant cytology result. In contrast, hypoechoic AG and
lateral nodule AG shape were not associated with malignancy (Table 6).
A predictive model for malignancy was formulated using multivariate logistic regression
(Table 7 and S1 Fig). The final model included two demographic factors, age and sex, and two
Table 2. Puncture technique details.
Needle type, n (%)
Cytological needle 153 (75.0)
Cytohistological needle 31 (15.20)
Missing 20 (9.80)






Aspiration technique, n (%)
Suction-syringe 135 (66.18)
Without syringe (slow-pull) 53 (25.98)
Others 6 (2.94)
Missing 10 (4.94)
Number of passes: median (IQR) 2.0 (1.0–3.0)
G, Gauges; IQR: inter quartile range
https://doi.org/10.1371/journal.pone.0216658.t002
Table 3. Staging of imaging procedures.









CT, computed tomography; PET, positron emission tomography
https://doi.org/10.1371/journal.pone.0216658.t003
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factors measured by EUS, echo pattern and AG shape. Among the factors ruled out were echo-
genicity and AG size > 30mm. Neither CT scan morphology nor PET scan uptake were con-
sidered for inclusion in the model. The selection of variables was taken in a count depending
the objectivity and clinical impact for each one. Although the variable ’EUS suspicion’ was the
most predictive parameter in the univariate analysis, it had not been ’included’ in the multivar-
iate analysis because it is a subjective variable and operator-depending.
The derived prediction model had good discrimination with area under the ROC curve
74% 95%CI 66% to 82% (Fig 4). Calibration was also acceptable, with good observed/expected
ratio for all strata of predicted risk. In Table 8, patient’s malignacy probability (calculated with
the estimated model) were grouped by decils and the observed event rates in each decil are pre-
sented. In the first decil of risk, with a probability of malignacy that ranged from 0.17 to 0.43, 6
of 18 malignacy cases were observed; in the last decil of risk, with a probability of malignacy
that ranged from 0.88 to 0.97, 17 of 18 malignacy cases were observed. Hosmer and Lemeshow
goodness of fit test suggested a rasonable fit of data to the estimated model (Chi2 5.8 p-value =
0.6689). Finally, a cut-off of malignacy probability defined two groups of patients: those with a










AG shapes, n (%)
Usual seagull shape 3 (1.47)
Seagull shape with enlargement of one of its limbs 84 (41.18)
Seagull shape with a global enlargement 46 (22.55)
Variegated morphology 68 (33.33)
Other 3 (1.47)





AG, Adrenal gland; EUS, Endoscopic ultrasound
https://doi.org/10.1371/journal.pone.0216658.t004




Atypical cells 2 (0.98)
Suspect 6 (2.94)
Insufficient sample 10 (4.90)
Diagnostic performance n (%) 186 (91.17)
Adverse effects n (%) 1 (0.49)
https://doi.org/10.1371/journal.pone.0216658.t005
EUS-guided TA of adrenal glands
PLOS ONE | https://doi.org/10.1371/journal.pone.0216658 June 6, 2019 8 / 16
postive result (probability of malignacy equal or above 0.4) and those with a negative result
(probability of malignacy below 0.4). Among positive patients 112 of 161 cases malignacy was
found and among negative patients 5 of 13 cases malignacy.
Discussion
This was a nationwide multicenter study with the largest number of cases of AG punctured by
EUS-TA, FNA or FNB, to date. All procedures were performed by a dedicated endosonogra-
pher expert in the diagnosis and staging of digestive and lung cancer. This study supports the
concept, previously introduced by other authors, that EUS-TA is a safe and accurate, mini-
mally invasive technique, and it may be considered as the first choice in the study of suspicion
in AGs, basically when this information can really help to the treatment strategy [3,11–13].
Nowadays, most imaging tests (PET, CT) are very powerful and reliable methods for the
staging of many tumors. But, specifically in the study of AGs, these tests still have some limita-
tions, and there remains the need to obtain biological material for pathological study. In the
radiological imaging literature, there is an evident limitation in the accuracy of these imaging
tests, as there is a considerable number of false-negatives (metastases misdiagnosed as adeno-
mas) and false-positives (adenomas classified as metastases) [2,15,16]. In the same line, this
current study has revealed a considerable percentage of cases with a benign profile in the EUS
image that obtained a result of malignancy in cytology. This suggests that it is still essential to
obtain a pathological sample to confirm a suspicion of metastasis that will produce a change in
the therapeutic attitude: radical surgical treatment is ruled out and treatment with systemic
chemotherapy or a palliative option are chosen instead.
There are many reasons to consider EUS-TA an attractive technique for the evaluation of
suspicious AGs. One obvious advantage of this endosonographer technique is in a lung cancer
Fig 3. ROC curve showing specificity (Spec) and sensitivity (Sens) of the diagnostic accuracy. Area under the curve:
0.70. Predictive value positive (PV+), predictive value negative (PV-).
https://doi.org/10.1371/journal.pone.0216658.g003
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scenario, where the EUS-TA can combine evaluation of a mediastinal tumor and of an
enlarged AG during the same procedure, plus without any irradiation [3].
A recent review on the role of EUS-FNA in the diagnosis of adrenal lesions considered 17
original articles (seven case reports, ten case series) including a total of 416 cases [11]. The
average AG size was 25.9mm; FNA needle size used was 19, 22, and 25 G, and the average
number of passes was two. A total of 25 right AGs were documented, no major AEs were
reported, and only one adrenal hemorrahge case was detected [17]. Regarding EUS image
Table 6. Variables associated with malignancy. Univariate analysis (n-186).
Malignants (122) Benigns (64) OR, CI 95% p-value
Age, mean (SD)
Age 64.0 (10.01) 67.6 (9.07) 0.96 (0.93–0.99) 0.018
Sex, n(%)
Men 27 (22.1%) 23 (35.9%) Reference
Women 95 (77.9%) 41 (64.1%) 1.97 (1.00–3.85) 0.049
CT scan morphology, na (%)
Normal 17 (15.3) 20 (35.1) Reference
2.96 (1.40–6.38)Pathological 94 (84.7) 37 (64.9) 0.005
PET scan uptake, nb (%)
Normcaptation 3 (4.29) 12 (35.3) Reference
11.4 (3.23–56.5)Hypercaptation 67 (95.7) 22 (64.7) <0.001
AG Morphologies, nc (%)




Enlargement of one of its limbs 46 (37.7) 32 (54.2)
Increase of global size 28 (23.0) 16 (27.1) 0.622
Variegated morphology 48 (39.3) 11 (18.6) 0.005
AG size > 30mm, nd (%)
No 51 (44.3) 38 (64.4) Reference
2.27 (1.19–4.38)Yes 64 (55.7) 21 (35.6) 0.013
Echo pattern, ne (%)
Homogeneous 42 (35.9) 34 (54.8) Reference
2.16 (1.15–4.07)Heterogeneous 75 (64.1) 28 (45.2) 0.016
EUS Suspicion, nf (%)
Benign 5 (4.55) 19 (46.3) Reference
17.3 (6.17–58.0)Malignant 105 (95.5) 22 (53.7) <0.001
EUS Indication, ng (%)
Lung neoplasia 90 (75.6%) 40 (63.5%) Reference
Other neoplasia 22 (18.5%) 13 (20.6%) 0.75 (0.35–1.68) 0.479
Unknown neoplasia 7 (5.88%) 10 (15.9%) 0.32 (0.11–0.89) 0.030
OR, Odds Ratio; CI, confidence interval; SD, standard deviation; CT, computed tomography; PET, Positron emission tomography; AG, Adrenal gland; EUS, Endoscopic
ultrasound; NA, not applicable






f 35 (18.8%) and
g 4 (2.2%).
https://doi.org/10.1371/journal.pone.0216658.t006
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findings, it is of note that a hypoechoic feature (usually related to malignancy) was not associ-
ated with a malignant cytological result [11,18]. In the same line, Eloubeidi et al reported inter-
esting findings: on a multivariable analysis an altered AG shape was a significant predictor of
malignancy, whereas a size >30mm and hypoechoic nature were not [13]. Based on size
>30mm alone, EUS had limited accuracy (68%). This finding is in striking contrast to the
strong correlation of this variable with the accuracy of the imaging tests [15].
This nationwide study reinforces the hypothesis that EUS-TA of AGs is a reproducible and
feasible technique, clearly assumable in endoscopy units that routinely perform this procedure.
The high diagnostic yield, with a small percentage of nondiagnostic biopsies and insufficient
samples, is similar to the data that come from an expert single-center in this area [10,13]. No
Table 7. Multivariate logistic model of malignancy (n-174).
Variables OR IC 95% p-value
Constant 2.39 (0.72–8.02) 0.15584
Female 0.44 (0.20–0.94) 0.03343
Age (5 years periods) 0.77 (0.63–0.93) 0.00986
Heterogeneous 2.56 (1.27–5.27) 0.00917
Global enlarged AG 1.67 (0.72–4.01) 0.24393
Variegated AG shape 3.25 (1.41–7.99) 0.00746
AG, adrenal gland.
https://doi.org/10.1371/journal.pone.0216658.t007
Fig 4. ROC curve of malignancy model. Estimator of the area under the curve: 0.74 CI 95% [0.66–0.82]. Area under
the ROC curve was estimated using the final model with the following factors: age, sex, echo pattern and adrenal gland
shape.
https://doi.org/10.1371/journal.pone.0216658.g004
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differences were encountered between cytological or cytohistological needles, and the rate of
confirmed malignancy was high, explained by the elevated proportion of lung cancer staging
included in this study. All patients were managed according to the cytological results obtained
by EUS-TA, a well-accepted method by oncologist and surgeons. Another strength offered by
this multicenter study is that it provides the largest case series of right AG punctures via trans-
duodenal approach with a similar prevalence (6%), compared with the recent review by Patil
et al [11,19].
It is important to note that some variables related to the EUS image (variegated AG shape,
heterogeneous echo-pattern, size >30mm) were clearly associated with the malignancy diag-
nosis, but the most accurate variable of EUS image was the endosonographer’s opinion. When
it was analyzed using the cytology, obtained by EUS-TA as a gold standard, the endoscopist’s
opinion showed an excellent S, good diagnostic accuracy but low Sp. This highlights the obser-
vation that EUS is an operator-depenent procedure, and the intuition of the endoscopist is
more credible and valuable than each variable taken separately.
As in previous papers, a hypoechoic EUS feature was not associated with a diagnosis of
malignancy by EUS-FNA [13,18]. In our opinion, the repetition of this finding in this study
can be considered a validation of the hypothesis that a hypoecohoic AG does not mean a
malignant AG, and does not exclude the performance of an EUS-TA.
The presented model allows estimation of the probability of a diagnosis of malignancy. The
best variables for the predictive multivariate logistic model were age, sex, echo pattern, and AG
shape determined by EUS. This model has an excellent S, good positive PV and negative PV,
but low Sp. Therefore, the probability of predicting the positive pathological AG is very high,
but the probability of predicting how negative the non-pathological AG is, is low. It should be
borne in mind that, due to a diagnosis confirmation bias, estimation of S and Sp is very likely
to be high and low, respectively.
In addition, both the probability of having a pathological AG and presenting a positive
result as well as the probability of having a non-pathological AG and presenting a negative
result are> 75%. But these results are determined by the prevalence; if the estimated preva-
lence (63% of malignant AG confirmed by EUS-TA in this study) does not reflect the usual
prevalence of pathological AG, the PPV value and the NPV value will not be credible and
should be ruled out.
Table 8. Observed and model predicted decils of malignancy.
Probability of malignancy No malignancy Malignancy
[0.166,0.432] 12 (67%) 6 (33%)
(0.432,0.5] 9 (47%) 10 (53%)
(0.5,0.558] 6 (40%) 9 (60%)
(0.558,0.619] 10 (56%) 8 (44%)
(0.619,0.705] 7 (41%) 10 (59%)
(0.705,0.755] 4 (24%) 13 (76%)
(0.755,0.792] 2 (11%) 16 (89%)
(0.792,0.848] 2 (12%) 15 (88%)
(0.848,0.876] 4 (24%) 13 (76%)
(0.876,0.971] 1 (6%) 17 (94%)
AG� No pathological Pathological
Positive (p�0.4) 49 112
Negative (p<0.4) 8 5
� If the probability of malignancy is >0.40, we would consider the adrenal gland (AG) as pathological.
https://doi.org/10.1371/journal.pone.0216658.t008
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No serious AEs were documented in this current study and other studies of EUS-FNA in
the AG, in contrast with the AE rate related to percutaneous biopsy [7–9]. No other organ
except the gastric or duodenal wall is punctured to access the AG. In this study no 19G needles
were used; only ‘fine’ (22 or 25 G) needles were utilized. This may have minimized AEs associ-
ated with puncture, such as bleeding and perforation. The use of cytohistological FNB needles
(‘core’, with a more agressive tip design) was not related to more AEs.
Regarding the risk of puncture of a previously undicovered pheochromocytoma, in this
study this occurred in two cases that were diagnosed with EUS-TA in which no previous urine
studies were performed. Although some authors recommend that urine studies should be per-
formed prior to attempting an AG guided-puncture, EUS-FNA of pheochromocytomas and
paragangliomas has been reported as safe [20–21]. Perhaps it would be safer to rule out pheo-
chromocytoma prior to puncturing an AG in patients without cancer, but in cases with known
primary malignancy, this may not be necessary [22].
Limitations
Our study has some limitations. Firstly, there is variability among the different centers, with
varying levels of expertise among the endosonographers; this may have instroduced some bias
in the results (e.g., technical aspects, measuring AG, interpretation of AG shape). Secondly, the
high proportion of lung cancers cases may have introduced a selection bias in the study popu-
lation. Thirdly, a retrospective study is associated with a lack of patient contact and missed fol-
low-ups; this is associated with a loss of some AEs.
There is also the limitation of the predictive model: the number of data used, although they
are all available to date, did not allow us to reserve part of these to perform a validation of the
model. Validation in a different sample of the development of the model presented here is
pending. Although the statistics to evaluate the predictive capacity of the model are quite satis-
factory, they may be under- or over-estimated due to a diagnostic confirmation bias or because
of a higher or lower than expected prevalence of malignancy in the sample.
In conclusion, EUS-TA of the AG is a safe, minimally invasive procedure, with an excellent
diagnostic yield. Some EUS image features are associated with a diagnosis of malignancy, and
this study suggests the possibility of developing a malignancy-predictive model for us prior to
the EUS procedure.
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